clinical trial · NCT06215716
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc·phase3·recruiting·n = 1,650
NASH With FibrosisMASH With FibrosisEfruxiferminPlacebo
brief summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
started
Dec 1, 2023
primary completion
Nov 1, 2032
completion
Nov 1, 2032
last updated
Apr 17, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol